Bionas and Primacyt to cooperate on cell-based assay for predicting
2 October 2006
Rostock and Schwerin, Germany. Bionas a specialist for
in vitro profiling the metabolic activity of cells, and PRIMACYT have
entered into a cooperation aimed at the development of a cell-based assay
using primary human hepatocytes for prediction of hepatotoxic effects in
response to test compounds.
Primary human hepatocytes, provided by
PRIMACYT, are cultivated directly on collagen-coated Bionas metabolic chips
SC1000 with PRIMACYT´s proprietary and chemically defined media. The chips
are then placed into the Bionas 2500 analyzing system to evaluate the effect
of test compounds. After a recovery period the hepatocytes can be re-used
for further experiments in Bionas 2500 analyzing system.
“Our study using
primary human hepatocytes and Bionas 2500 analyzing system shows very
promising results and could be ideally suited to predict hepatotoxic effects
in vitro,” says Dr. Ralf Ehret, general manager of Bionas GmbH.
liver toxicity is a major concern of the pharmaceutical industry and
non-immortalized primary human hepatocytes can be used as biosensors for the
analysis of drugs, food additives and chemicals. A cell-based assay based on
the Bionas 2500 analyzing system and primary hepatocytes may aid compound
selection in the drug-discovery process and may reduce both the number of
animal studies and preclinical development time.